Skip to main content
. 2017 Jan 13;12(1):e0169624. doi: 10.1371/journal.pone.0169624

Fig 4. The effect of an initial aggressive immunosuppression (Alemtuzumab, anti-CD 52 therapeutical antibody targeting mature lymphocytes; Infliximab, anti-TNF-therapeutical antibody targeting T-lymphocytes and Methylprednisolone, shortly before and after Tx, followed by two weeks of Tacrolimus treatment) on T and B cells depletion and their subsequent recovery within 12 months in TAC- and SIR-group.

Fig 4

CD3+ for T cells, CD4+ for TH lymphocytes, CD8+ for cytotoxic lymphocytes and CD19+ for B cells. Data are presented as means and SEM.